Evidence map›Paper›PMID 16239394›Full record

ReviewAnnals of the rheumatic diseases2005

How does B cell depletion therapy work, and how can it be improved?

E A Clark, J A Ledbetter

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of the rheumatic diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside.International journal of molecular sciences · 2020
    Review
  8. Review
  9. Phenotypic identification of CD19Archives of medical science : AMS · 2019
    Article
  10. Mature IgDNature communications · 2019
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. B cells as therapeutic targets in SLE.Nature reviews. Rheumatology · 2010
    Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

E A ClarkDepartment of Immunology and National Primate Research Center, Box 357330, University of Washington, Seattle, WA 98195, USA. eclark@bart.rprc.washington.edu
J A Ledbetter

Funding

YILMA SIV VACCINIA VACCINE TRIALP51RR000166 · NCRR · UNIVERSITY OF WASHINGTON · PI HU, SHIU-LOK · 1985 to 2011
$161.1M
NCRR NIH HHS RR00166
6 · The paper itself

Abstract

The past few years have seen a surge of interest in B cell depletion therapy for patients with rheumatoid arthritis. This paper outlines the possible mechanism(s) by which B cell depletion therapy works. It is likely there is more than one mechanism and the relative importance of each mechanism depends on the target cell. These include CD20-induced apoptosis, complement dependent cytotoxicity, antibody dependent cell-mediated cytotoxicity, and selective targeting and depletion of B cell subsets. The implications of these mechanisms in the further improvement of B cell depletion therapy in rheumatoid arthritis and other autoimmune diseases are discussed.

Indexed as

Arthritis, RheumatoidAutoimmune DiseasesB-LymphocytesCytotoxicity, ImmunologicHumansLymphocyte Depletion

Identifiers

PMID16239394
PMCPMC1766898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.